Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c03084 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Hua Tian und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and P…. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Histone Deacetylase Inhibitors, Drug Design. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
The concurrent targeting of Fms-like tyrosine kinase 3 (FLT3)/VEGFR2/Histone deacetylase (HDAC) represents a novel and promising therapeutic strategy for acute myeloid leukemia. In this work, we hybridized essential pharmacophores from sorafenib and SAHA (vorinostat) and then conducted structure-activity relationship studies to identify two lead compounds 26 and 32 that potently inhibit FLT3, VEGFR2, and HDAC in a nanomolar range. In cell evaluation, compounds 26 and 32 exhibited potent proliferative activities against a panel of leukemia cells including MV4-11 and MOLM-13. Western blotting analysis also showed that compounds 26 and 32 suppressed the phosphorylation of FLT3, STAT3, and ERK1/2 and increased histone H3 acetylation in a dose-dependent manner, indicating the effective inhibition of FLT3, VEGFR2, and HDAC. Supported by its pharmacokinetic properties, compound 26 showed remarkable anticancer efficacy in a MV4-11 xenograft model. Additionally, it demonstrated superior efficacy compared to midostaurin and gilteritinib in the Ba/F3-FLT3-ITD-N701K xenograft model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- Beijing Key Laboratory of Active Substances Discovery and Druggability Evaluation, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
- CAMS Key Laboratory of Small Molecule Immuno-Oncology Drug Discovery, Chinese Academy of Medical Sciences, Beijing 100050, China.
- Kyinno Biotechnology Co., Ltd, F2 Building, Yizhuang Biomedical Park, No. 88, Kechuang Six Street, BDA, Beijing 101111, China.
- Beijing Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China.
ORCID-Profile: Heng Xu
Förderung
- Chinese Academy of Medical Sciences
Zitieren
APA
Tian, H., Liu, Y., Lin, S., Deng, J., Zhang, Q., Hao, F., Tang, Y., Xiong, T., Zhang, K., Shi, G., Luo, L., Peng, S., Sheng, L., Ji, M., & Xu, H. (2025). Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c03084
Vancouver
Tian H, Liu Y, Lin S, Deng J, Zhang Q, Hao F, et al. Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c03084
BibTeX
@article{Tian2025,
author = {Tian, Hua and Liu, Yichen and Lin, Songwen and Deng, Jialing and Zhang, Qinghua and Hao, Feng and Tang, Yao and Xiong, Tianning and Zhang, Kehui and Shi, Ge and Luo, Lijun and Peng, Shouguo and Sheng, Li and Ji, Ming and Xu, Heng},
title = {Design, Synthesis, and Biological Evaluation of Novel Fms-Like Tyrosine Kinase 3/VEGFR2/Histone Deacetylase Inhibitors for the Treatment of Acute Myeloid Leukemia},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c03084}
}
EUVIMED